Description
CCT-128930 is a pyrrolopyrimidine that inhibits Akt and exhibits anticancer chemotherapeutic activity. In hepatoma cancer cells, this compound induces G1 phase cell cycle arrest, apoptosis, and autophagy, upregulates expression of p21, p27, and p53, and suppresses cell proliferation. CCT-128930 also induces G1 phase cell cycle arrest in glioblastoma cells and limits tumor growth in animal models with breast cancer xenografts.